Drug intelligence / Profile preview

LAS41007

Development stage: Phase 3
Lead developer: Almirall
Modality: Small Molecules
Administration: Topical

Overview

LAS41007 was a topical drug developed by Almirall S.A. for the treatment of actinic keratosis. The mechanism of action was undefined according to available information. The drug completed Phase III clinical trials in Germany but was discontinued in July 2012.

Brand names: Solacutan
Other names: diclofenac sodium 3% geldiclofenac sodium gel

Targets

PGHS-1 (Prostaglandin G/H Synthase 1)

Beyond the preview

Go deeper on LAS41007.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on LAS41007.

Explore the full profile